Prostate cancer bone metastases acquire resistance to androgen deprivation via WNT5A-mediated BMP-6 induction
Lee G, Kang D, Ha Y, Jung Y, Chung J, Min K, Kim T, Moon K, Chung J, Lee D, Kim W, Kim I. Prostate cancer bone metastases acquire resistance to androgen deprivation via WNT5A-mediated BMP-6 induction. British Journal Of Cancer 2014, 110: 1634-1644. PMID: 24518599, PMCID: PMC3960605, DOI: 10.1038/bjc.2014.23.Peer-Reviewed Original ResearchMeSH KeywordsAdultAndrogen AntagonistsAnilidesBone Morphogenetic Protein 6Bone NeoplasmsCell CommunicationCell Growth ProcessesCell Line, TumorHumansMaleMiddle AgedNeoplasm MetastasisNitrilesOrchiectomyProstatic Neoplasms, Castration-ResistantProto-Oncogene ProteinsReceptors, AndrogenRetrospective StudiesStromal CellsTosyl CompoundsWnt ProteinsWnt-5a ProteinConceptsCastration-resistant prostate cancerBone stromal cellsBone metastasesBone morphogenetic protein 6Castration resistanceCaP cell linesStromal cellsProstate cancerPrimary androgen deprivation therapyProstate-specific antigen progressionProstate cancer bone metastasisAndrogen-deprived mediumBone-tumor interactionAndrogen deprivation therapyFirst-line therapyCancer bone metastasisMetastatic prostate cancerAbsence of androgenAndrogen-depleted conditionsNF-κB pathwayCell linesPolymerase chain reaction arrayBMP-6 expressionAdvanced CaPDeprivation therapy